|
DE3839126A1
(de)
*
|
1988-11-19 |
1990-05-23 |
Hoechst Ag |
Renin-hemmende harnstoffderivate von dipeptiden, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
|
|
FI904441A7
(fi)
*
|
1989-09-12 |
1991-03-13 |
Hoechst Ag |
Aminohappojohdannaisia, joilla on reniiniä estäviä ominaisuuksia, menetelmiä niiden valmistamiseksi, näitä sisältäviä aineita ja niiden käyttö
|
|
US6313094B1
(en)
|
1990-12-11 |
2001-11-06 |
Japan Energy Corporation |
β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
|
|
US5554728A
(en)
*
|
1991-07-23 |
1996-09-10 |
Nexstar Pharmaceuticals, Inc. |
Lipid conjugates of therapeutic peptides and protease inhibitors
|
|
WO1993002674A1
(en)
*
|
1991-08-02 |
1993-02-18 |
Smithkline Beecham Corporation |
Hiv protease inhibitors
|
|
US6071895A
(en)
*
|
1992-03-11 |
2000-06-06 |
Narhex Limited |
Polar-substituted hydrocarbons
|
|
MXPA93002392A
(es)
|
1992-03-11 |
2005-02-04 |
Narhex Ltd |
Derivados amino de hidrocarburos-oxo e hidroxi-substituidos.
|
|
US5679688A
(en)
*
|
1992-03-11 |
1997-10-21 |
Narhex Limited |
Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
|
|
US5888992A
(en)
*
|
1992-03-11 |
1999-03-30 |
Narhex Limited |
Polar substituted hydrocarbons
|
|
US5972990A
(en)
*
|
1992-04-10 |
1999-10-26 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
|
US5559256A
(en)
*
|
1992-07-20 |
1996-09-24 |
E. R. Squibb & Sons, Inc. |
Aminediol protease inhibitors
|
|
IL110898A0
(en)
*
|
1993-09-10 |
1994-11-28 |
Narhex Australia Pty Ltd |
Polar-substituted hydrocarbons
|
|
JPH08277287A
(ja)
*
|
1995-02-09 |
1996-10-22 |
Mitsubishi Chem Corp |
インダゾール類およびその用途
|
|
US6423689B1
(en)
|
1997-12-22 |
2002-07-23 |
Warner-Lambert Company |
Peptidyl calcium channel blockers
|
|
US6376242B1
(en)
*
|
1999-09-21 |
2002-04-23 |
Emory University |
Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
|
|
ATE343562T1
(de)
|
2000-03-23 |
2006-11-15 |
Elan Pharm Inc |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
|
EP1299352B1
(en)
|
2000-06-30 |
2005-12-28 |
Elan Pharmaceuticals, Inc. |
Compounds to treat alzheimer's disease
|
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
|
US6846813B2
(en)
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
|
AU2002230848B2
(en)
|
2000-12-14 |
2008-01-24 |
The Brigham And Women's Hospital, Inc. |
Inflammatory markers for detection and prevention of diabetes mellitus
|
|
US6982264B2
(en)
|
2001-06-27 |
2006-01-03 |
Elan Pharmaceuticals, Inc. |
Substituted alcohols useful in treatment of Alzheimer's disease
|
|
WO2003094856A2
(en)
|
2002-05-09 |
2003-11-20 |
The Brigham And Women's Hospital, Inc. |
1l1rl-1 as a cardiovascular disease marker and therapeutic target
|
|
AU2003229016A1
(en)
*
|
2002-05-10 |
2003-11-11 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
|
|
WO2005018561A2
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
|
EP1668008A4
(en)
*
|
2003-08-28 |
2009-02-25 |
Nitromed Inc |
NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
|
|
AU2004315596B2
(en)
|
2003-08-29 |
2011-11-24 |
President And Fellows Of Harvard College |
Inhibitors of cellular necrosis
|
|
US7781219B2
(en)
|
2003-12-05 |
2010-08-24 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
|
AU2005207037A1
(en)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
|
EP2927693A1
(en)
|
2004-10-06 |
2015-10-07 |
The Brigham and Women's Hospital |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
|
CA2574535A1
(en)
*
|
2004-11-15 |
2006-05-26 |
Nitromed, Inc. |
Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
|
|
EP1846380A4
(en)
*
|
2005-01-21 |
2010-02-17 |
Nicox Sa |
HETEROCYCLIC NITROGEN MONOXIDE DONOR COMPOSITIONS CONTAINING CARDIOVASCULAR COMPOUNDS, AND METHODS OF USING THE SAME
|
|
AP2764A
(en)
*
|
2005-01-31 |
2013-09-30 |
Mylan Lab Inc |
Hydroxylated nebivolol metabolites
|
|
AU2006336387A1
(en)
*
|
2005-02-16 |
2007-08-02 |
Nicox S.A. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
|
EP1858863A1
(en)
*
|
2005-02-28 |
2007-11-28 |
Nitromed, Inc. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
|
JP2008533031A
(ja)
*
|
2005-03-09 |
2008-08-21 |
ニトロメッド インコーポレーティッド |
アンギオテンシンiiアンタゴニストの有機酸化窒素増強塩、組成物および使用法
|
|
CA2610694A1
(en)
|
2005-05-31 |
2006-12-07 |
Mylan Laboratories, Inc. |
Compositions comrising nebivolol
|
|
US20090018091A1
(en)
*
|
2005-08-02 |
2009-01-15 |
Nitromed, Inc. |
Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
|
|
US20090054381A1
(en)
*
|
2005-10-04 |
2009-02-26 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
|
US7838023B2
(en)
*
|
2005-11-16 |
2010-11-23 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
|
EP1968584A2
(en)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
|
EP1971340A2
(en)
*
|
2005-12-22 |
2008-09-24 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
|
EP2302395B1
(en)
|
2006-06-07 |
2015-04-15 |
Health Diagnostic Laboratory, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
|
US8362066B2
(en)
|
2006-11-17 |
2013-01-29 |
Treventis Corporation |
Compounds and methods for treating protein folding disorders
|
|
EP2891885A3
(en)
|
2007-04-18 |
2015-10-14 |
Health Diagnostic Laboratory, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
|
US7828840B2
(en)
*
|
2007-11-15 |
2010-11-09 |
Med Institute, Inc. |
Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
|
|
AU2009322836B2
(en)
|
2008-11-25 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
|
AU2009322613A1
(en)
|
2008-12-05 |
2011-06-23 |
Merck Sharp & Dohme Corp. |
Nitrooxy derivatives as angiotensin II receptor antagonists
|
|
JP5411300B2
(ja)
|
2009-02-26 |
2014-02-12 |
メルク・シャープ・アンド・ドーム・コーポレーション |
可溶性グアニレートシクラーゼ活性化剤
|
|
KR20120139723A
(ko)
|
2010-02-01 |
2012-12-27 |
더 호스피탈 포 식 칠드런 |
재발협착증의 치료 및 예방을 위한 원격 허혈 처치
|
|
CN102939054A
(zh)
|
2010-03-31 |
2013-02-20 |
儿童医院 |
远端缺血处理改进心肌梗死之后的结果的用途
|
|
US8623846B2
(en)
|
2010-05-21 |
2014-01-07 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
|
US9108920B2
(en)
|
2010-10-29 |
2015-08-18 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate heterocyclic derivatives
|
|
MX351305B
(es)
|
2011-01-20 |
2017-10-09 |
Merck Sharp & Dohme |
Antagonistas del receptor de mineralocorticoides.
|
|
JO3350B1
(ar)
|
2011-03-07 |
2019-03-13 |
Merck Sharp & Dohme |
مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
|
|
EP2697203B1
(en)
|
2011-04-13 |
2017-05-24 |
Merck Sharp & Dohme Corporation |
Mineralocorticoid receptor antagonists
|
|
EP2701512B1
(en)
|
2011-04-26 |
2017-04-05 |
Merck Sharp & Dohme Corp. |
Aldosterone synthase inhibitors
|
|
WO2012151114A1
(en)
|
2011-05-02 |
2012-11-08 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
US9108947B2
(en)
|
2011-10-31 |
2015-08-18 |
Merck Sharp & Dohme Corp. |
Inhibitors of the Renal Outer Medullary Potassium channel
|
|
US9139585B2
(en)
|
2011-10-31 |
2015-09-22 |
Merck Sharp & Dohme Corp. |
Inhibitors of the Renal Outer Medullary Potassium channel
|
|
NZ728724A
(en)
|
2012-05-11 |
2018-03-23 |
Reset Therapeutics Inc |
Carbazole-containing sulfonamides as cryptochrome modulators
|
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
|
AU2013296803B2
(en)
|
2012-08-01 |
2018-03-08 |
Eric Ostertag |
Free flowing, frozen compositions comprising a therapeutic agent
|
|
EP2925322B1
(en)
|
2012-11-29 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
|
US9717714B2
(en)
|
2012-12-19 |
2017-08-01 |
Merck Sharp & Dohme Corp. |
Spirocyclic CETP inhibitors
|
|
WO2014145022A1
(en)
|
2013-03-15 |
2014-09-18 |
President And Fellows Of Harvard College |
Hybrid necroptosis inhibitors
|
|
EP3079701B1
(en)
|
2013-12-11 |
2021-08-11 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
|
EP3079700B1
(en)
|
2013-12-11 |
2020-11-25 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
|
US10000484B2
(en)
|
2013-12-18 |
2018-06-19 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassim channel
|
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
|
EP3149487B1
(en)
|
2014-05-29 |
2020-02-12 |
Geneticure LLC |
Improved therapeutic regimen for hypertension
|
|
US10011572B2
(en)
|
2014-07-29 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
ES2799503T3
(es)
|
2014-10-31 |
2020-12-18 |
Ngm Biopharmaceuticals Inc |
Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
|
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
|
US10245264B2
(en)
|
2015-05-27 |
2019-04-02 |
Merck Sharp & Dohme Corp. |
Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
|
|
WO2016191335A1
(en)
|
2015-05-28 |
2016-12-01 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
|
US20180230166A1
(en)
|
2015-07-13 |
2018-08-16 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
|
WO2018057409A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Sharp & Dohme Corp. |
Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders
|
|
MX2019005679A
(es)
|
2016-11-18 |
2019-08-14 |
Merck Sharp & Dohme |
Derivados de indol de utilidad como inhibidores de diacilglicerido o-aciltransferasa 2.
|
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
|
US20220281886A1
(en)
|
2019-05-22 |
2022-09-08 |
Merck Sharp Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
|
EP3972590A4
(en)
|
2019-05-22 |
2023-06-14 |
Merck Sharp & Dohme LLC |
NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USED TO TREAT CARDIOMETABOLIC DISEASES, KIDNEY DISEASES AND DIABETES
|
|
WO2021041770A1
(en)
|
2019-08-30 |
2021-03-04 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist compounds
|
|
CN116133660B
(zh)
|
2020-07-22 |
2025-05-02 |
詹森药业有限公司 |
可用作因子XIa抑制剂的化合物
|
|
US11814364B2
(en)
|
2021-03-18 |
2023-11-14 |
Janssen Pharmaceutica Nv |
Pyridine N-oxide derivatives useful as factor XIa inhibitors
|
|
US11919881B2
(en)
|
2021-03-18 |
2024-03-05 |
Janssen Pharmaceutica Nv |
Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
|
|
US11845748B2
(en)
|
2021-03-18 |
2023-12-19 |
Janssen Pharmaceutica Nv |
Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
|
|
US11897880B2
(en)
|
2021-04-30 |
2024-02-13 |
Janssen Pharmaceutica Nv |
7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
|
|
US12286429B2
(en)
|
2021-07-22 |
2025-04-29 |
Janssen Pharmaceutica Nv |
5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
|
|
US11958856B2
(en)
|
2021-07-22 |
2024-04-16 |
Janssen Pharmaceutica Nv |
Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
|
|
IL310851A
(en)
|
2021-08-19 |
2024-04-01 |
Merck Sharp & Dohme Llc |
Compounds for the treatment of diseases associated with PCSK9 activity
|